Ki67 antibody mouse specific - HS-398 108

Ki67 is a marker protein for proliferating cells
Rabbit monoclonal recombinant IgG
Cat. No.: HS-398 108
Amount: 100 µl
Price: $415.00
Cat. No. HS-398 108 100 µl purified recombinant IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: not tested yet
IP: not tested yet
ICC: 1 : 500 gallery  
IHC: 1 : 500 (see remarks) gallery  
IHC-P: 1 : 500 gallery  
Clone Rb311H2
Subtype IgG1 (κ light chain)
Immunogen Synthetic peptide corresponding to AA 1234 to 1252 from mouse Ki67 (UniProt Id: E9PVX6)
Reactivity Reacts with: mouse (E9PVX6).
No signal: human (P46013), rat (D4A0Y6).
Other species not tested yet.
Remarks

This antibody is a chimeric antibody based on the monoclonal rat antibody clone 311H2. The constant regions of the heavy and light chains have been replaced by rabbit specific sequences. Therefore, the antibody can be used with standard anti-rabbit secondary reagents. The antibody has been expressed in mammalian cells.
IHC: Heat-mediated antigen retrieval (in citrate buffer pH 6) is required for immunohistochemical staining.

Data sheet hs-398_108.pdf
Cat. No.: HS-398 108
Amount: 100 µl
Price: $415.00

Detection of proliferating murine cells in a humanized mouse spleen using anti-mouse Ki67

Background

Expression of the nuclear protein Ki 67 is strictly associated with cell proliferation and preferentially expressed during the late G1, S, G2 and M phases of the cell cycle. Resting cells (G0 phase) lack Ki 67 expression .
Immunohistochemical detection of Ki 67 is a simple and reproducible method to determine the tumour proliferative index and is a predictive and prognostic biomarker in certain types of human cancer, such as breast cancer, gastric cancer or prostate cancer. Moreover, higher Ki 67 scores may be associated with increased tumor sensitivity to radiation therapy and chemotherapy.
In preclinical and clinical studies Ki 67 expression is used as a pharmacodynamic biomarker. Absence of a decrease in Ki 67 early in treatment might be predictive of therapeutic failure.

Protocols for HS-398 108